A vital role for Interleukin-21 in the control of a chronic viral infection

Science

Volumn 324, Issue 5934, 2009, Pages 1572-1576

  Yi, John S ^a   Du, Ming ^a   Zajac, Allan J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 21;

ANTIMICROBIAL ACTIVITY; BLOOD; DISEASE CONTROL; GENE; VIRAL DISEASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS MENINGITIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; INTERLEUKINS; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; VIRAL LOAD;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 67649203681     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1175194     Document Type: Article

References (31)

1. D. Moskophidis, F. Lechner, H. Pircher, R. M. Zinkernagel, Nature 362, 758 (1993).
2. M. Matloubian, R. J. Concepcion, R. Ahmed, J. Virol. 68, 8056 (1994).
3. A. Oxenius, R. M. Zinkernagel, H. Hengartner, Immunity 9, 449 (1998).
4. A. Gallimore et al., J. Exp. Med. 187, 1383 (1998).
5. A. J. Zajac et al., J. Exp. Med. 188, 2205 (1998).
6. M. J. Fuller, A. Khanolkar, A. E. Tebo, A. J. Zajac, J. Immunol. 172, 4204 (2004).
7. D. G. Brooks, L. Teyton, M. B. Oldstone, D. B. McGavern, J. Virol. 79, 10514 (2005).
8. N. L. Letvin, B. D. Walker, Nat. Med. 9, 861 (2003).
9. E. J. Wherry, J. N. Blattman, K. Murali-Krishna, R. van der Most, R. Ahmed, J. Virol. 77, 4911 (2003).
10. M. Battegay et al., J. Virol. 68, 4700 (1994).
11. M. G. von Herrath, M. Yokoyama, J. Dockter, M. B. Oldstone, J. L. Whitton, J. Virol. 70, 1072 (1996).
12. G. T. Belz, D. Wodarz, G. Diaz, M. A. Nowak, P. C. Doherty, J. Virol. 76, 12388 (2002).
13. C. Bourgeois, H. Veiga-Fernandes, A. M. Joret, B. Rocha, C. Tanchot, Eur. J. Immunol. 32, 2199 (2002).
14. E. M. Janssen et al., Nature 421, 852 (2003).
15. D. J. Shedlock, H. Shen, Science 300, 337 (2003).
16. J. C. Sun, M. J. Bevan, Science 300, 339 (2003).
17. C. M. Smith et al., Nat. Immunol. 5, 1143 (2004).
18. A. Khanolkar, M. J. Fuller, A. J. Zajac, J. Immunol. 172, 2834 (2004).
19. J. Parrish-Novak et al., Nature 408, 57 (2000).
20. K. Brandt, P. B. Singh, S. Bulfone-Paus, R. Ruckert, Cytokine Growth Factor Rev. 18, 223 (2007).
21. R. Spolski, W. J. Leonard, Annu. Rev. Immunol. 26, 57 (2008).
22. K. Ozaki et al., Science 298, 1630 (2002).
23. T. Korn et al., Nature 448, 484 (2007).
24. N. Fazilleau, L. Mark, L. J. McHeyzer-Williams, M. G. McHeyzer-Williams, Immunity 30, 324 (2009).
25. Materials and methods are available as supporting material on Science Online.
26. R. Ahmed, A. Salmi, L. D. Butler, J. M. Chiller, M. B. Oldstone, J. Exp. Med. 160, 521 (1984).
27. M. J. Buchmeier, A. J. Zajac, in Persistent Viral Infections, R. Ahmed, I. S. Y. Chen, Eds. (Wiley, West Sussex, UK, 1999), pp. 575-605.
28. R. Zeng et al., J. Exp. Med. 201, 139 (2005).
29. M. G. Dodds et al., Cancer Immunol. Immunother. 58, 843 (2009).
30. C. Boni et al., J. Virol. 81, 4215 (2007).
31. We thank L. Harrington, P. Goepfert, B. Hahn, G. Shaw, and the members of the Zajac laboratory for discussions and assistance. This work was supported by grants AI049360 and AI067993 (to A.J.Z.) and T32 AI007051 (to J.S.Y.) from the NIH.